INFILTRATION DU CHALAZION
Incision and Curettage Versus Steroid Injection for the Treatment of Chalazia: A Meta-Analysis.
*Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; and †Department of Ophthalmology, The Edith Wolfson Medical Center, Holon, Israel.
To compare the efficacy of the chalazia treatment modalities of incision and curettage (I&C) and intralesional steroid injections (SI).
Full publications of randomized controlled trials that compared I&C with SI were identified. Aggregated success rate, weighted summary proportions, and weighted pooled relative risk for success were calculated for each method.
Data were extracted from 8 publications that met these criteria, between 1984 and 2013. There were 288 patients treated by SI with aggregate success rate of 60.4% with 1 injection and 72.5% with 1 or 2 injections. The range of the success rate was 8.7 to 86.7% for 1 injection. The success rate for the second SI was 19.0%, with a range of 0% to 53.8%. There were 264 patients treated by I&C with a larger aggregate success rate of 78.0% with 1 procedure and 86.7% with 1 or 2 procedures (p < 0.05 for both comparisons). The range of the success rates was 60.0% to 92.0% for 1 I&C. The success rate for the second I&C was 90.65%, with a range of 83.3% to 100%. Compared with I&C, the overall relative risk for SI with 1 procedure was 0.77 (p = 0.05), while the overall relative risk for 1 or 2 procedures was 0.89 (p = 0.002).
This analysis shows that I&C is more effective than SI with 1 procedure. This benefit is reduced when comparing 1 or 2 attempts of I&C and SI. Studies failed to show a difference in the incidence of complications with either procedure.
Int Ophthalmol. 2014 Oct;34(5):1049-53. doi: 10.1007/s10792-014-9904-1. Epub 2014 Jan 19.
Intralesional triamcinolone acetonide injection for the treatment of primary chalazions.
Department of Ophthalmology, Caritas Medical Centre, 111 Wing Hong St., Kowloon, Hong Kong Special Administrative Region, China.
The aim of this study was to investigate the safety and efficacy of intralesional triamcinolone acetonide (TA) injection in the treatment of primary chalazions not responding to conservative treatment. Patient medical records were retrospectively reviewed for all consecutive patients that received intralesional TA injection by a single surgeon between January 2012 and March 2013 for the treatment of unresolved primary chalazions despite 1 month of conservative treatment. The dose of TA injection ranged from 2 to 6 mg (40 mg/mL) depending on the size of the chalazion. The main outcome measures included time to resolution, time to 50 % size reduction, and complications from the treatment. During the study period, 48 chalazions from 38 patients were treated by intralesional TA injection. A 50 % reduction in size was achieved in 81.3 % of chalazions in 4 weeks and 83 % achieved complete resolution in 6 weeks. The mean time to complete resolution was 15.7 ± 10.0 days. There were no complications noted from the injections; 14.6 % required subsequent incision and curettage and 2.1 % required a second TA injection for complete resolution. Intralesional TA injection is a safe, simple, and effective procedure for the management of primary chalazions and may be considered as an alternative to incision and curettage in cases not responding to conservative treatment.
Efficacité du traitement par injection du chalazion
Risques et effets indésirables possibles
Arch Soc Esp Oftalmol. 2020 Mar;95(3):141-145. doi: 10.1016/j.oftal.2019.12.007. Epub 2020 Jan 27.
Bilateral and multifocal central serous chorioretinopathy after injecting triamcinolone into a chalazion.
[Article in English, Spanish]
We present a case of bilateral and multifocal central serous chorioretinopathy that developed one month after an intra-chalaziontriamcinolone acetonide injection. Central serous chorioretinopathy spontaneously resolved during observation 3 months after diagnosis. We believe that central serous chorioretinopathy can occur as a complication of administration of depot corticosteroids even at a low dose.
Copyright © 2020 Sociedad Española de Oftalmología. Publicado por Elsevier España, S.L.U. All rights reserved.